Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Journal Scan / Research · March 16, 2015

ACC.15: Alirocumab Reduces LDL Levels in the ODESSEY Trial

The New England Journal of Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The New England Journal of Medicine
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
N. Engl. J. Med 2015 Mar 15;[EPub Ahead of Print], JG Robinson, M Farnier, M Krempf, et al for the ODYSSEY LONG TERM Investigators

Further Reading